Catherine S. Diefenbach, MD, Reviews the Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL
June 29, 2022

Catherine S. Diefenbach, MD spoke about the approval of lisocabtagene maraleucel for the treatment of relapsed/refractory large B-cell lymphoma following 1 prior therapy.

FDA Grants Fast Track Designation to PDS0101 Plus Pembrolizumab in Advanced Head and Neck Cancer
June 29, 2022

Fast track designation was granted to PDS0101 plus pembrolizumab, which is currently being assessed in the phase 2 VERSATILE study in patients with recurrent or metastatic human papillomavirus 16–positive head and neck cancer.

European Medicines Agency Recommends T-DXd for Approval in European Union in Advanced HER2+ Breast Cancer
June 29, 2022

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended for approval trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive breast cancer.

Punctual, Kinetic MRD Analysis May Be MCL Natural History, Progression, and Outcomes Indicator
June 29, 2022

Punctual and kinetic minimal residual disease analysis could be a robust predictor of mantle cell lymphoma’s natural history and could represent an adaptable model for continuous patient risk assessment.

Utilizing Daratumumab in the Frontline Setting Versus in Later Lines in MM
June 29, 2022

Daratumumab effectiveness is evaluated as a frontline treatment approach versus in later lines of therapy in patients with multiple myeloma.

Selection and Duration of Therapy in Transplant-Ineligible NDMM
June 29, 2022

Expert panelists consider which regimen they would use, and for what duration, in the setting of transplant-ineligible, newly diagnosed multiple myeloma.

Clinical Case 1: A 41-year-old Patient with HER2+ Metastatic Breast Cancer
June 29, 2022

Rita Nanda, MD, leads a discussion of the first clinical scenario, a 41-year-old woman with HER2+ metastatic breast cancer who progressed on docetaxel/trastuzumab/pertuzumab.

Overview of HER2+ Metastatic Breast Cancer (mBC)
June 29, 2022

To begin the program, an expert panel of leaders in the management of HER2+ metastatic breast cancer provides an overview of the disease landscape.

Patient Profile 2: A 72-Year-Old With Transplant-Ineligible NDMM
June 29, 2022

The panel moves on to review the profile of a patient with transplant-ineligible, newly diagnosed multiple myeloma managed with dara-Rd on the MAIA trial.

Mark Pegram, MD, Reviews Utility of Breast Cancer Index in Early-Stage HR+ Breast Cancer
June 28, 2022

Mark Pegram, MD, spoke about using the Breast Cancer Index and Clinical Treatment Score post-5 years to determine outcomes for patients with early-stage hormone receptor–positive breast cancer treated with adjuvant endocrine therapy.